Cargando…
Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report
Osimertinib is the most efficient first‐line drug, with least adverse effects, for metastatic non‐small‐cell lung carcinoma (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations with exon 19 deletion or exon 21 L858R mutations. Herein, we present a 68‐year‐old woman who had chronic hep...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977162/ https://www.ncbi.nlm.nih.gov/pubmed/35146920 http://dx.doi.org/10.1111/1759-7714.14346 |